-
2023-504161-22-00
4
2021-06-04
Active Discoid and/or Subacute Cutaneous Lupus Erythematosus
(DLE/SCLE
-
2023-505615-21-00
5
2021-04-28
Muscle Invasive Bladder Cancer
-
2023-506525-11-00
5
2021-04-19
Primary Membranous Nephropathy (pMN)
-
2023-509066-38-00
4
2021-04-16
Atrial Fibrillation
-
2022-500256-37-00
5
2021-04-08
Prevention of persistent anogenital HPV infection and disease caused b
-
2024-514467-26-00
4
2021-04-07
Indolent Systemic Mastocytosis
-
2023-506962-30-00
5
2021-03-29
Non-alcoholic steatohepatitis (NASH)
-
2023-506899-27-00
5
2021-03-25
Relapsed or refractory diffuse large B-cell lymphoma
-
2022-502705-15-00
5
2021-03-08
High-risk muscle-invasive bladder cancer
-
2023-507695-52-00
5
2021-03-05
Mantle cell lymphoma
-
2024-514502-31-00
5
2021-01-11
Prurigo Nodularis
-
2023-508290-81-00
5
2020-12-18
Immunoglobulin G4-related disease (IgG4-RD)
-
2023-504830-23-00
5
2020-12-16
B-cell Lymphoma
-
2024-516653-44-00
5
2020-11-30
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
-
2022-502611-10-00
5
2020-11-24
Primary Progressive Multiple Sclerosis (PPMS)
-
2023-509358-72-00
5
2020-11-23
Diffuse large B-cell lymphoma
-
2022-502052-30-00
5
2020-10-27
Unresectable Esophageal Squamous Cell Carcinoma
-
2023-506365-64-00
5
2020-10-16
Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
-
2024-514404-13-00
5
2020-10-01
Atopic Dermatitis
-
2023-506877-37-00
5
2020-09-28
Relapsed/Refractory Multiple Myeloma
-
2022-502841-91-00
5
2020-08-12
Crohn’s Disease
-
2023-505830-89-00
6
2020-08-05
metastatic castrate resistant prostate cancer (mCRPC)
-
2024-515953-52-00
5
2020-07-24
Post-Essential Thrombocythaemia Myelofibrosis
-
2023-503628-22-00
5
2020-07-16
Lupus Nephritis (LN)